TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16222197
Drug: Terbinafine 625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 625 mg/day (n = 25)
Study: 10150266
Drug: MS Contin
Normalized name: MS Contin
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MS Contin 30 mg
Study: 10150266
Drug: MS Contin
Normalized name: MS Contin
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MS Contin 60 mg
Study: 10150266
Drug: Oramorph SR
Normalized name: Oramorph SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oramorph SR 60 mg
Study: 3122699
Drug: Bupropion hydrochloride
Normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion hydrochloride (dosage not specified)
Study: 28590765
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (rest, NSAİİ, bracing, exercise)
Study: 23163825
Drug: Losartan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 200 mg/day
Study: 20817148
Drug: Group Person-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Person-Based Cognitive Therapy (PBCT)
Study: 16679299
Drug: Lercanidipine 10-20
Normalized name: lercanidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 10-20 mg once daily
Study: 16679299
Drug: Losartan 50-100
Normalized name: losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 50-100 mg once daily
Study: 15572814
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G + Chloramphenicol (n:46)
Study: 8215565
Drug: Early lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early lipid containing parenteral nutrition
Study: 8215565
Drug: Late lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late lipid containing parenteral nutrition
Study: 28985195
Drug: Dexamethasone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.1 mg/kg IV bolus 10 hours before surgery)
Study: 25765602
Drug: Constraint‐Induced Aphasia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐Induced Aphasia Therapy (CIAT)
Study: 25765602
Drug: Semantic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semantic therapy (BOX)
Study: 19204212
Drug: GP training
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP training plus cost-free nicotine replacement medication and/or bupropion hydrochloride
Study: 19204212
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GP training plus GP remuneration and cost-free nicotine replacement medication and/or bupropion hydrochloride
Study: 17322142
Drug: Anidulafungin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anidulafungin (200 mg IV on day 4, followed by 100 mg IV on days 5-13)
Study: 17322142
Drug: Tacrolimus (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (5 mg orally on days 1 and 13)
Study: 9806253
Drug: GnRHa (nafarelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa (nafarelin acetate/Synarel) at a dosage of 200 microg three times daily until HCG administration
Study: 9806253
Drug: GnRHa (nafarelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa (nafarelin acetate/Synarel) reduced to 200 microg twice daily as ovarian stimulation was initiated
Study: 3347522
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cephalocaudal stroking and multisensory hammock
Study: 29795368
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (PS) 2 g/d
Study: 18441530
Drug: Combined HB‐Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined HB‐Hib vaccine (Hebervac HB‐Hib)
Study: 18441530
Drug: HB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB vaccine (Heberbiovac‐HB) and Hib vaccine (QuimiHib)
Study: 16569462
Drug: Maintenance gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance gemcitabine (1,250 mg/m² on days 1 and 8 every 21 days) plus best supportive care (GEM arm)
Study: 8737166
Drug: 250 g
Normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 g preload
Study: 8737166
Drug: 500 g
Normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g preload
Study: 8737166
Drug: 750 g
Normalized name: Isopropyl Alcohol 750 g in 1 kg TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 g preload
Study: 1559192
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for four weeks prior to quinapril therapy)
Study: 3926036
Drug: Low residue
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low residue liquidized diet (Isocal) administered to treatment group
Study: 3926036
Drug: Routine intravenous
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine intravenous therapy administered to control group
Study: 31672256
Drug: Visco-ease™ oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visco-ease™ oral spray
Study: 17323135
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K supplementation (500 microg daily)
Study: 15334317
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (Rb) 400 mg twice a day, tetracycline (T) 1 g twice a day, metronidazole (M) 500 mg three times a day for 14 days (RbTM)
Study: 15334317
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (Rb) 400 mg twice a day for 14 days and azithromycin (A) 500 mg once a day for 7 days (RbA)
Study: 2666019
Drug: Cycloprovera (medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycloprovera (medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg)
Study: 2666019
Drug: HRP-102 (norethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRP-102 (norethisterone enanthate 50 mg + estradiol valerate 5 mg)
Study: 140037
Drug: Minoxidil in
Normalized name: Product containing minoxidil in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil in combination with frusemide and propranolol
Study: 140037
Drug: Hydrallazine in
Normalized name: Hydrallazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrallazine in combination with frusemide and propranolol
Study: 28409242
Drug: Topical ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ropivacaine with 20 mg ketamine (RK group)
Study: 28409242
Drug: Topical ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ropivacaine with saline (RS group)
Study: 20694567
Drug: Ultrasonic vibration
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasonic vibration (V) with G-Cem (GC)
Study: 20694567
Drug: Static seating
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Static seating pressure (P) with G-Cem (GC)
Study: 2406105
Drug: Active specific
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active specific immunotherapy using the patient's tumor cells to create a vaccine
Study: 7413719
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg daily of cannabidiol (CBD) for 30 days in healthy volunteers
Study: 7413719
Drug: 200-300 mg
Normalized name: allopurinol 300 MG / lesinurad 200 MG [Duzallo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-300 mg daily of cannabidiol (CBD) for 4 1/2 months in epilepsy patients
Study: 7413719
Drug: Placebo (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glucose capsules) for 30 days in healthy volunteers
Study: 24028755
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of salbutamol (15 μg/kg IBW/hour)
Study: 19660492
Drug: Extended-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release morphine
Study: 19660492
Drug: Hydrocodone plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone plus acetaminophen
Study: 18261269
Drug: Adverse drug
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse drug reactions in Group A and B
Study: 15089956
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of an oral analgesic algorithm derived from systematic reviews
Study: 11791961
Drug: Wheat germ
Normalized name: Wheat Germ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat germ (WG) 2 g, 3 times a day for 10 days
Study: 11791961
Drug: Metronidazole (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (250 mg 3 times a day) plus WG
Study: 11791961
Drug: Placebo (cornstarch,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cornstarch, 2 g, 3 times a day)
Study: 11791961
Drug: Metronidazole (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (250 mg 3 times a day) plus placebo
Study: 8072199
Drug: CSF 39-300
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSF 39-300 (10 micrograms/kg daily via intravenous infusion for 21 days)
Study: 28929861
Drug: Ulipristal Acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal Acetate (10 mg/d)
Study: 24923077
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg bevacizumab
Study: 18640473
Drug: Metformin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1.5 g/d (MET group)
Study: 12844280
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (benzodiazepines and conventional antipsychotics)
Study: 12844280
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (ziprasidone, risperidone, olanzapine)
Study: 28061907
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI 72/9.6 μg BID
Study: 28061907
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI 36/9.6 μg BID
Study: 28061907
Drug: Tiotropium DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium DPI 18 μg once daily
Study: 28061907
Drug: FF DPI
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FF DPI 12 μg BID
Study: 21437522
Drug: Topical combination
Normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical combination of benzoyl peroxide 5% and clindamycin 1%
Study: 21437522
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel cream
Study: 19884606
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral analysis system of psychotherapy (CBASP) and continued pharmacotherapy (MEDS)
Study: 19884606
Drug: Brief supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief supportive psychotherapy (BSP) and continued pharmacotherapy (MEDS)
Study: 19884606
Drug: Continued optimized
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued optimized pharmacotherapy (MEDS) alone
Study: 17301637
Drug: Smoking (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking (25 g/day or more)
Study: 17301637
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in serum cholesterol of 1 mmol/l
Study: 11141144
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 mg once daily for one week, then 20 mg once daily for 11 weeks
Study: 11092283
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus metformin
Study: 9321764
Drug: Isoniazid as
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid as probe drug
Study: 8462143
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg sublingual GTN
Study: 29370143
Drug: CHO-REPLACE (15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-REPLACE (15% carbohydrate solution; 221.4 ± 59.3 g maltodextrin)
Study: 29370143
Drug: CHO-DEFICIT (non-caloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-DEFICIT (non-caloric artificially-sweetened placebo solution)
Study: 23254579
Drug: High-dose ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ARB (n = 22)
Study: 15845509
Drug: Vibrio cholerae
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibrio cholerae 638 vaccine (10^9 CFU buffered with 1.3% NaHCO3)
Study: 15845509
Drug: Vibrio cholerae
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibrio cholerae 638 vaccine
Study: 10355070
Drug: Sotalol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (2 x 160 mg)
Study: 10355070
Drug: Quinidine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine + Verapamil (3 x 160 mg + 3 x 80 mg)
Study: 20022206
Drug: Perioperative β-blockers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative β-blockers
Study: 18971181
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of nalmefene (2 mg)
Study: 18971181
Drug: Multiple intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intravenous doses of nalmefene (2 mg once daily for 6 days)
Study: 12801736
Drug: Multiple-dose activated
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose activated charcoal (50 g every 6 hours for 3 days)
Study: 12801736
Drug: Multiple-dose activated
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose activated charcoal
Study: 11192146
Drug: Rivastigmine 6
Normalized name: rivastigmine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 6 to 12 mg/d
Study: 2862297
Drug: Oral triazolam
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral triazolam 0.5 mg
Study: 29527973
Drug: Pharmacist-led intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led intervention (barbers encouraged meetings with specialty-trained pharmacists who prescribed drug therapy)
Study: 25214778
Drug: Indacaterol 75
Normalized name: INDACATEROL 75MCG CAP,INHL,30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 75 μg
Study: 1695304
Drug: Isradipine 5
Normalized name: isradipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5 mg b.i.d.
Study: 366145
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro levamisole added to lymphocyte culture prior to drug treatment
Study: 25736164
Drug: Siltuximab 11
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Siltuximab 11 mg/kg every 3 weeks
Study: 21272712
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy plus physical therapy (MET plus PT)
Study: 10228117
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP; 250 microgram twice a day)
Study: 10228117
Drug: Salbutamol (Sb;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (Sb; 400 microgram twice a day)
Study: 8912948
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of meta-chlorophenylpiperazine (MCPP) at a dose of 0.06 mg/kg
Study: 24798350
Drug: Infliximab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (3 mg/kg) combined with methotrexate (MTX) therapy, administered at weeks 0, 2, 6, and 14.
Study: 24798350
Drug: MTX monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX monotherapy (Control group).
Study: 23789705
Drug: T100 PARI
Normalized name: PARIS QUADRIFOLIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: T100 PARI (150 mg/1.5 mL) nebulized with a PARI eFlow nebulizer
Study: 23789705
Drug: TOBI (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOBI (300 mg/5 mL) nebulized with a PARI LC PLUS nebulizer
Study: 16685253
Drug: Methylphenidate (MP)
Normalized name: 6 MP
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MP) 40 to 60 mg orally
Study: 15078394
Drug: Prophylactic advisory
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic advisory device replacement recommended for prior appropriate ICD therapy
Study: 7798068
Drug: Indapamide 1.25
Normalized name: indapamide 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 1.25 mg once daily for 8 weeks
Study: 7798068
Drug: Indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 2.5 mg once daily for 8 weeks
Study: 7798068
Drug: Indapamide 1.25
Normalized name: indapamide 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 1.25 mg
Study: 2750695
Drug: Tryptophan (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptophan (3 g)
Study: 2750695
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 g lactose)
Study: 776880
Drug: 5% methenamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% methenamine in a firm stick gel, applied daily to one palmar or plantar surface
Study: 22169724
Drug: Three stages
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three stages of 5-aminolevulinic acid-photodynamic therapy (ALA-PDT)
Study: 17431366
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of prulifloxacin (600 mg) before the operation
Study: 11717015
Drug: Aprotinin (10(6)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin (10(6) kallikrein inhibitory units (KIU) loading dose followed by the same dose during chest closure)
Study: 9219164
Drug: Fosinopril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril, 10 mg by mouth daily (treated group)
Study: 2972054
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (240 micrograms, 40 micrograms each nostril, repeated twice at 15 min intervals)
Study: 27206914
Drug: 25% PAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% PAA treatment
Study: 27206914
Drug: 17% EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17% EDTA treatment
Study: 18523440
Drug: 1.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/day plant sterols in margarine divided equally at each of the three daily meals (three times per day)
Study: 18523440
Drug: 1.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/day plant sterols in margarine with breakfast (single-BF)
Study: 9799203
Drug: Oral methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine load (0.1 g/kg)
Study: 9345462
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon beta-1a (IFN-beta-1a) 6.0 x 10(6) IU (30 micrograms) administered by weekly intramuscular injections
Study: 24953046
Drug: Intensive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid-lowering therapy with rosuvastatin
Study: 24953046
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with pravastatin
Study: 15746633
Drug: Aspirin administration
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin administration before surgery
Study: 15746633
Drug: Non-aspirin (control)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aspirin (control) group
Study: 9808219
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg RRR-alpha-tocopheryl acetate
Study: 1266422
Drug: D(‐)penicillamine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: D(‐)penicillamine (900 mg) plus salicylate (1500 mg)
Study: 1266422
Drug: Prednisolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (10 mg) plus salicylate (1500 mg)
Study: 28432468
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous acetaminophen administered over 15, 60, or 120 minutes
Study: 25545331
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (600 mg/d ubiquinol) with simvastatin 20 mg/d
Study: 25545331
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with simvastatin 20 mg/d
Study: 18628521
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone administration (T(4) 50 microg and T(3) 0.67 microg/kg.d)
Study: 16950363
Drug: Chaperonin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chaperonin 10 (5 mg)
Study: 16950363
Drug: Chaperonin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chaperonin 10 (7.5 mg)
Study: 16950363
Drug: Chaperonin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chaperonin 10 (10 mg)
Study: 16950363
Drug: Chaperonin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chaperonin 10 (all doses)
Study: 8942005
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin injection using buffered regular insulin